^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ZG006
i
Other names: ZG006
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Suzhou Zelgen
Drug class:
CD3 agonist, DLL3 inhibitor
Related drugs:
6d
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=105, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Sep 2024
Enrollment open • Trial initiation date • Metastases
|
ZG006
6d
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (clinicaltrials.gov)
P1/2, N=78, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
ZG006
3ms
A Phase 1 Dose Escalation Study of ZG006 in Patients with Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1 trial
|
ZG006
7ms
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (clinicaltrials.gov)
P1/2, N=78, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial • Metastases
|
ZG006
10ms
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=105, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
ZG006
1year
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=54, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
ZG006
over1year
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=54, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
ZG006
Share via
